Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Pediococcus acidilactici is a lactic acid bacterium increasingly investigated for its potential probiotic benefits, including in gastrointestinal disorders such as colitis. Several preclinical studies (primarily in animal models) have demonstrated that P. acidilactici may help alleviate colitis symptoms. These studies suggest that the bacterium can modulate the gut microbiota, enhance intestinal barrier integrity, and reduce pro-inflammatory cytokines (such as TNF-α and IL-6) in chemically induced colitis models. For example, mouse studies have found that administering P. acidilactici lessened colonic inflammation and improved clinical scores of colitis induced by agents like dextran sulfate sodium (DSS).

However, there is a lack of robust human clinical trial data directly supporting the efficacy of P. acidilactici for the treatment or management of colitis (including ulcerative colitis or Crohn’s disease). Most evidence is preclinical, and while promising, extrapolation to human disease is premature. Systematic reviews on probiotics for colitis generally focus on other strains (e.g., Lactobacillus, Bifidobacterium), with P. acidilactici rarely featured.

In summary, the use of Pediococcus acidilactici for colitis is justified by emerging scientific (preclinical) evidence, but high-quality clinical trials in humans are needed. The current evidence strength is rated 2/5, indicating preliminary but not definitive support.

More about Pediococcus acidilactici
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by Pediococcus acidilactici

Products containing Pediococcus acidilactici